As part of the global strategic alliance between Merck and Pfizer to develop and commercialize avelumab, an investigational immune checkpoint inhibitor, the companies have entered a collaboration with Dako, an Agilent Technologies company, for the development of a potential companion diagnostic test (CDx).  Financial terms were not disclosed.   The agreement allows the three companies to work together to develop the CDx to assess programmed death-ligand 1 (PD-L1) protein expression levels in t...